
Accelerate Diagnostics AXDX
Quarterly report 2024-Q3
added 11-07-2024
Accelerate Diagnostics Total Assets 2011-2026 | AXDX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Accelerate Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 65 M | 83 M | 93.4 M | 134 M | 185 M | 126 M | 82.9 M | 139 M | 69.8 M | 43.4 M | 17.2 M | 6.26 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 185 M | 6.26 M | 87.1 M |
Quarterly Total Assets Accelerate Diagnostics
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.3 M | 22.9 M | 31.4 M | 39.3 M | 49.9 M | 51 M | 65 M | 75.8 M | 58.7 M | 70.4 M | 83 M | 81.2 M | 94 M | 92.7 M | 93.4 M | 93.4 M | 93.4 M | 93.4 M | 134 M | 134 M | 134 M | 134 M | 185 M | 185 M | 185 M | 185 M | 126 M | 126 M | 126 M | 126 M | 82.9 M | 82.9 M | 82.9 M | 82.9 M | 139 M | 139 M | 139 M | 139 M | 69.8 M | 69.8 M | 69.8 M | 69.8 M | 43.4 M | 43.4 M | 43.4 M | 43.4 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 6.11 M | 6.25 M | 6.26 M | 6.26 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 185 M | 6.11 M | 81.9 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Anixa Biosciences
ANIX
|
16.1 M | $ 3.03 | -2.26 % | $ 98.3 K | ||
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | ||
|
Castle Biosciences
CSTL
|
531 M | $ 39.83 | 1.7 % | $ 1.11 B | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
Brainsway Ltd.
BWAY
|
94.3 M | $ 23.52 | -2.2 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 34.0 | 0.68 % | $ 366 M | ||
|
Exact Sciences Corporation
EXAS
|
5.93 B | $ 102.43 | 0.13 % | $ 19 B | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 26.13 | -0.44 % | $ 790 M | ||
|
BioNano Genomics
BNGO
|
76.7 M | $ 1.3 | -11.56 % | $ 1.65 M | ||
|
Guardant Health
GH
|
1.49 B | $ 111.99 | 1.37 % | $ 13.7 B | ||
|
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
95.3 M | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
77.5 B | $ 218.32 | -0.59 % | $ 160 B | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
1.98 B | $ 66.61 | -0.1 % | $ 4.61 B | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
DexCom
DXCM
|
6.26 B | $ 73.22 | -1.05 % | $ 28.3 B | ||
|
NeoGenomics
NEO
|
1.64 B | $ 11.91 | -3.95 % | $ 1.51 B | ||
|
CareDx, Inc
CDNA
|
467 M | $ 20.33 | -2.26 % | $ 1.09 B | ||
|
Celcuity
CELC
|
245 M | $ 108.09 | -3.59 % | $ 4.26 B | ||
|
DarioHealth Corp.
DRIO
|
96.4 M | $ 10.14 | -1.55 % | $ 288 M | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
Personalis
PSNL
|
270 M | $ 9.27 | -7.02 % | $ 549 M | ||
|
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
6.3 B | $ 144.04 | -3.77 % | $ 22.9 B | ||
|
QIAGEN N.V.
QGEN
|
5.69 B | - | - | $ 10.6 B | ||
|
IQVIA Holdings
IQV
|
26.9 B | $ 229.24 | -2.71 % | $ 41.6 B | ||
|
Charles River Laboratories International
CRL
|
7.53 B | $ 208.45 | -1.53 % | $ 10.7 B | ||
|
Thermo Fisher Scientific
TMO
|
97.3 B | $ 575.61 | -2.79 % | $ 220 B | ||
|
Trinity Biotech plc
TRIB
|
103 M | $ 0.81 | -7.96 % | $ 61.9 M | ||
|
Twist Bioscience Corporation
TWST
|
642 M | $ 40.92 | -1.59 % | $ 2.45 B | ||
|
Medpace Holdings
MEDP
|
2.1 B | $ 581.54 | -1.94 % | $ 18 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 185.97 | 1.99 % | $ 20.6 B | ||
|
Biodesix
BDSX
|
97.2 M | $ 9.61 | -0.57 % | $ 1.25 B | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | ||
|
Precipio
PRPO
|
18.1 M | $ 24.39 | 0.54 % | $ 31.7 M | ||
|
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 269.91 | 0.04 % | $ 22.6 B | ||
|
Mettler-Toledo International
MTD
|
3.24 B | $ 1 376.67 | -1.16 % | $ 29.2 B | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 179.26 | -3.57 % | $ 14.8 B | ||
|
IDEXX Laboratories
IDXX
|
3.29 B | $ 673.4 | -0.49 % | $ 55.5 B |